--- title: "MaxCyte | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 9.651 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286314397.md" datetime: "2026-05-13T20:37:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286314397.md) - [en](https://longbridge.com/en/news/286314397.md) - [zh-HK](https://longbridge.com/zh-HK/news/286314397.md) --- # MaxCyte | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 9.651 M Revenue: As of FY2026 Q1, the actual value is USD 9.651 M, beating the estimate of USD 7.298 M. EPS: As of FY2026 Q1, the actual value is USD -0.04, beating the estimate of USD -0.076. EBIT: As of FY2026 Q1, the actual value is USD -7.62 M. #### Net Loss and Accumulated Deficit MaxCyte, Inc. reported a net loss of - $4.8 million for the three months ended March 31, 2026, with an accumulated deficit of - $266.2 million as of the same date. #### Revenue Total revenue for the three months ended March 31, 2026, was $9.7 million, representing a -7% decrease from $10.4 million in the prior year period. ##### Core Revenue Core revenue decreased by -25% to $6.2 million for the three months ended March 31, 2026, from $8.2 million in the prior year. Instrument revenue decreased by -7% to $1.3 million from $1.4 million. PA revenue decreased by -41% to $2.3 million from $3.9 million. License revenue decreased by -17% to $2.1 million from $2.5 million. Assay service revenue increased by 32% to $0.2 million from $0.1 million. Other service revenue increased by 15% to $0.3 million from $0.3 million. ##### Non-core Revenue Non-core revenue, primarily from Strategic Platform License (SPL) milestones and royalties, increased by 60% to $3.4 million for the three months ended March 31, 2026, from $2.1 million in the prior year period. ##### Geographic Revenue - Revenue inside the United States was $6.6 million, down from $8.0 million in the prior year. - Revenue outside the United States was $3.0 million, up from $2.4 million in the prior year. #### Gross Profit Gross profit decreased by -9% to $8.1 million for the three months ended March 31, 2026, compared to $8.9 million in the prior year. The gross margin was 84%, down from 86% in the prior year. Cost of goods sold increased by 5% to $1.6 million. #### Operating Expenses Total operating expenses decreased by -33% to $14.3 million for the three months ended March 31, 2026, from $21.2 million in the prior year. Research and development expenses decreased by -35% to $3.9 million from $5.9 million. Sales and marketing expenses decreased by -40% to $3.4 million from $5.7 million. General and administrative expenses decreased by -30% to $6.0 million from $8.5 million. Depreciation and amortization expenses decreased by -4% to $1.0 million from $1.1 million. #### Operating Loss Operating loss improved to - $6.2 million for the three months ended March 31, 2026, from - $12.3 million in the prior year. #### Other Income Interest income decreased by -29% to $1.4 million from $2.0 million. #### Cash Flows Net cash used in operating activities was - $8.2 million, an improvement from - $14.4 million in the prior year. This was due to a net loss of - $4.8 million, offset by $2.2 million in non-cash expenses, and - $5.6 million in changes in operating assets and liabilities. Net cash provided by investing activities was $2.7 million, primarily from $28.0 million in maturities of investments, offset by $25.1 million in purchases of investments and $0.2 million for capital expenditures. Net cash provided by financing activities was $5,000 from the exercise of stock options. #### Outlook and Strategy MaxCyte, Inc. expects total revenue to increase as customer programs advance, markets grow, and the installed base under SPL license agreements expands. The company anticipates continued growth in PA and instrument sales and licenses to cell therapy customers as preclinical programs move into clinical development and commercialization. MaxCyte also expects to attract new customers due to growth in the cell therapy pipeline and a shift towards non-viral approaches, though revenue may fluctuate due to timing uncertainties. ### Related Stocks - [MXCT.US](https://longbridge.com/en/quote/MXCT.US.md) ## Related News & Research - [River Global Investors Discloses Investment in MaxCyte with 6.1% Stake](https://longbridge.com/en/news/286427947.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [Sangoma Announces Third Quarter Fiscal 2026 Results | SANG Stock News](https://longbridge.com/en/news/286317217.md) - [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md)